Trident Lifeline Q1 FY27 Results (BSE: 543616)
Signal: Margin expansion
The read
Trident Lifeline delivered a strong Q1FY27 beat on the trajectory established last year: consolidated revenue up 47% YoY, PAT up 64% YoY, with OPM expanding ~140bps to ~22.7% — the 4th consecutive quarter of margin expansion. The driver was clear operating leverage: fixed/semi-fixed costs (employee +23%, finance cost -12%, depreciation +38%) all grew slower than the 47% revenue rise, while input costs also tailed off 200bps as % of revenue. Standalone PAT grew slower (+36%) than consolidated, consistent with group profit concentration in subsidiaries. EPS of ₹4.27 tracks PAT closely — no dilution.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹33.71 Cr | +47.0% | -32.5% |
| EBIT | ₹7.64 Cr | +74.2% | |
| Net profit | ₹5.03 Cr | +64.3% | |
| EPS | ₹4.27 | +60.5% | |
| EBIT margin | 22.7% |
P&L walk
Revenue grew 47% YoY; cost of materials as % of revenue improved 200bps to 17.9% (input cost tailwind), employee cost rose slower (+23%) than revenue, depreciation and finance cost also grew slower, delivering 74% EBIT growth vs 47% revenue growth — a clear operating leverage story, with EBITDA margin expanding ~140bps to ~22.7%.
Key positives
- Revenue growth of 47% YoY to ₹3,371 lakh, accelerating from prior-year Q1 growth rate.
- OPM expanded ~140bps YoY to ~22.7% — 4th consecutive quarter of margin expansion.
- PAT up 64% YoY to ₹503 lakh (after minority), faster than revenue growth.
- Finance cost declined 12% YoY despite revenue growth, indicating deleveraging.
- EPS ₹4.27, up 60.5% YoY — no material dilution.
Key concerns
- QoQ revenue declined 32.5% from Q4FY26 (₹4,995 lakh), which is typical seasonality in pharmaceuticals or a lumpy revenue pattern that needs monitoring.
Research and educational content only. Not investment advice.